Q-omics provides the consensus-scored FUNDC2P1 profile across patient tissues and cancer cell-line models. FUNDC2P1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FUNDC2P1 is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, FUNDC2P1 RNA expression shows 16,547 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, BLCA, and UVM as cancer lineages where FUNDC2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FUNDC2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FUNDC2P1 survival associations across molecular data types. FUNDC2P1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FUNDC2P1 RNA expression–survival associations across cancer types. High FUNDC2P1 expression shows unfavorable associations in UVM, LIHC, UCEC and HNSC, but favorable associations in MESO and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for FUNDC2P1 RNA expression.
This table summarizes FUNDC2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for FUNDC2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FUNDC2P1 shows lower tumor expression in BLCA, UCEC, KICH and LUAD and higher tumor expression in LIHC and CHOL. The BLCA box plot shows higher FUNDC2P1 RNA expression in normal versus tumor tissue (log2 FC = −0.530, t-test p = .002).
This table shows molecular features associated with FUNDC2P1 in patient tissues and cancer cell lines. In patient samples, FUNDC2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
